United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

manx healthcare ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - betamethasone; clioquinol - cream - 0.1 %w/w + 3.0 percent weight/weight - corticosteroids, potent, combinations with antiseptics; betamethasone and antiseptics

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - betamethasone acetate 3 mg in 1 ml - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.  synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see use in specific populations ( error! hyperlink reference not valid. )] .

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breast

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - calcipotriol, quantity: 52.2 microgram/g; betamethasone dipropionate, quantity: 643 microgram/g (equivalent: betamethasone, qty microgram/g) - ointment - excipient ingredients: dl-alpha-tocopherol; oleyl alcohol; liquid paraffin; white soft paraffin - indicated for the once daily topical treatment of plaque-type psoriasis vulgaris amenable to topical therapy.

United States - English - NLM (National Library of Medicine)

warrick pharmaceuticals corporation - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - ointment - 0.5 mg in 1 g - augmented betamethasone dipropionate ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. augmented betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

Ireland - English - HPRA (Health Products Regulatory Authority)

aristo pharma gmbh - betamethasone; calcipotriol - gel - 50 microgram/g +0.5 milligram(s)/gram - calcipotriol, combinations

Namibia - English - Namibia Medicines Regulatory Council

msd pty ltd - betamethasone valerate, tolnaftate , gentamicin sulphate, clioquinol - cream - each gram cream contains : betamethasone valerate 0,5 mg, tolnaftate 10,0 mg, gentamicin sulphate 1,0 mg, clioquinol 10 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chemidex pharma ltd - betamethasone valerate; clioquinol - cutaneous ointment - 1mg/1gram ; 30mg/1gram